Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
31
Oct |
In Europe Patients Benefit From New Radiation TherapyCategory: Radiology / Nuclear Medicine | Leave a Comment |
A new, innovative form of radiation based on verified scientific facts will be available to patients all over Europe within the next few decades. The official kick-off meeting of the Community project ULICE (Union of LIght Ions Centres in Europe), which the European Union supported with nearly 10 million euros, was held in the fall of 2009 in the Department of Radiooncology and Radiation Therapy of the Heidelberg University Hospital.
|
31
Oct |
2009 Katz Prizes In Cardiovascular Research Announced By Columbia University Medical CenterCategory: Cardiovascular / Cardiology | Leave a Comment |
Columbia University Medical Center today announces the winners of the 4th annual Katz Prizes in Cardiovascular Research, with the senior scientist prize being awarded to an internationally renowned researcher from the National Institutes of Health, and the young investigator prize recognizing a cardiovascular researcher actively studying left ventricular assist devices and heart function. The senior scientist award goes to Elizabeth G. Nabel, M.D.
|
31
Oct |
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseCategory: Medic | Leave a Comment |
Background Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa can effectively increase hemoglobin …
|
31
Oct |
Treatment of Anemia in Chronic Kidney Disease — Strategies Based on EvidenceCategory: Medic | Leave a Comment |
(No abstract is available for this citation)
|
30
Oct |
H1N1 Testing Data Presented At Infectious Diseases Society Of America ConferenceCategory: Swine Flu | Leave a Comment |
The Phoenix-based non-profit Translational Genomics Research Institute (TGen) has announced that, along with a business collaborator, it will submit a request to the U.S. Food and Drug Administration for emergency use of a new test to diagnose the 2009 H1N1 swine flu virus. Details about TGen’s test will be presented Sunday (Nov. 1) at the 47th annual meeting of the Infectious Diseases Society of America (IDSA), being held today through Sunday (Oct. 29-Nov. 1) in Philadelphia.
|
30
Oct |
Rapid Growth Scoops Pathology Diagnostics Erbi AwardCategory: Medical Devices / Diagnostics | Leave a Comment |
The rapid organic growth and commercial potential of newcomer Pathology Diagnostics Ltd. has won it the 2009 ERBI Start-up Award, which is sponsored by the East of England Development Agency. Pathology Diagnostics Ltd. has achieved a six figure turnover without upfront equity investment. It provides a one-stop solution for human tissue diagnostics.
|
30
Oct |
Medical Device Manufacturers Launch Ad To Head Off $40B Tax On Their ProductsCategory: Medical Devices / Diagnostics | Leave a Comment |
The Medical Device Manufacturers Association is starting a $200,000 radio and print ad campaign aimed at stopping Congress from imposing more than $40 billion in taxes on their goods, Roll Call reports. “The spots have been placed in Capitol Hill publications, including Roll Call, Congressional Quarterly and Politico, as well as on local news radio station WTOP.
|
30
Oct |
Ascent Healthcare Solutions Receives 510(K) Clearance To Reprocess Biosense Webster SoundStar™ 3D Diagnostic Ultrasound CatheterCategory: MRI / PET / Ultrasound | Leave a Comment |
Ascent Healthcare Solutions, a leader in delivering healthcare resource sustainability, announced that it has received the industry’s first and only 510(k) clearance from the U.S. Food and Drug Administration (FDA) to reprocess the Biosense Webster SoundStar™ 3D Diagnostic Ultrasound Catheter. With this new clearance, Ascent continues to lead the charge in bringing sustainability to healthcare.
|
29
Oct |
Primary Care and Accountable Care — Two Essential Elements of Delivery-System ReformCategory: Medic | Leave a Comment |
(No abstract is available for this citation)
|
29
Oct |
NeoChord Enrolls First Patient In European Clinical TrialCategory: Medical Devices / Diagnostics | Leave a Comment |
NeoChord, Inc., a venture-backed, Minneapolis-based medical technology company, announced today that it has enrolled the first patient in its European clinical trial. The trial, known as TACT (transapical artificial chordae tendineae) is being conducted in Germany, Denmark, Czech Republic and Norway. “We are very pleased with the early results of this first procedure,” said Per Wierup and Sten Lyager Nielsen, the cardiac surgeons who performed the surgery.